Kidney Health Redefined

NephroSant is a biotechnology company that develops pioneering diagnostic tools for the early detection of risk of kidney disease or injury and lifetime monitoring of kidney health.

Chronic Kidney Disease:
A Global Public Health Crisis

1 in 9
Chronic Kidney Disease, or CKD, is a global public health crisis. 1 out of 9 people worldwide have CKD.

1 in 3
80 million American adults are at risk for CKD, and 120,000 people annually develop End-Stage Renal Disease (ESRD) leading to kidney transplantation.

1 in 6
In the United States, 37 million people are affected by CKD, yet 90% of them don’t know they have it.

QSant™ is a noninvasive, urine-based test that optimizes early detection of kidney rejection risk. By providing an actionable, individual risk score, it empowers clinicians to personalize care.

LEARN MORE ABOUT QSANT

About 10% of kidney transplants every year are re-transplants in patients with graft loss.
This underscores the need to maximize the success of future transplants by identifying rejection risk and managing patients in a more proactive way.

ABOUT NEPHROSANT

NephroSant is a biotechnology company that develops pioneering diagnostic tools for the early detection of risk of kidney disease or injury and long-term monitoring of kidney health. NephroSant is a diagnostic platform company dedicated to understanding the spectrum of kidney health. Utilization of NephroSant’s testing tools help identify the risk of transplant rejection, support kidney health and detect the risk of kidney rejection earlier. QSant is a noninvasive, urine-based test that supports early detection of kidney rejection risk by providing an actionable, individual risk score that can empower clinicians to personalize care.